Emerging evidence demonstrates that the antitumor effect of anti-CD47 therapy can be enhanced when it is combined with temozolomide and anti–PD-1 treatments (90), carnitine palmitoyltransferase 1 inhibitor (etomoxir) (92), or autophagy depletion (93) in GBM mouse models. The gene discussed is CD47; the disease is glioblastoma.